Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02574455
Title ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT)
Acronym ASCENT
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immunomedics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.